UroStream Archives - Page 19 of 24

ESMO Asia 2024 | Professors Hailiang Zhang and Xiaolin Lu’s Team Unveils Multi-Omics Insights into Translocation Renal Cell Carcinoma (TRCC)

By El Bachir MOURABIT 2024.12.13

Translocation renal cell carcinoma (TRCC), though rare, constitutes a significant proportion of kidney cancer cases among young and middle-aged patients. Analyzing its characteristics in depth can aid in accurate diagnosis, treatment planning, and prognosis evaluation. At the 2024 ESMO Asia Annual Meeting in Singapore, a study by the team from Fudan University Shanghai Cancer Center on TRCC was showcased in a poster presentation. Urology Frontier invited Professors Hailiang Zhang and Xiaolin Lu to share key findings from their research.

Dr. Hao Zeng: Advancing Uro-Oncology with Cutting-Edge Technologies and Promoting Standardized Care in Grassroots Settings

By Mourabit Halima 2024.12.12

Focusing on global progress while highlighting Chinese innovations, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Uro-Oncology Annual Meeting of the Sichuan Anti-Cancer Association were successfully held in Chengdu, Sichuan. Organized by the Sichuan Anti-Cancer Association and hosted by its Urological and Male Reproductive Tumors Committee in collaboration with the Department of Urology at West China Hospital, Sichuan University, the conference brought together experts to discuss the latest advancements. Following the event, Urology Frontier had the privilege of interviewing the conference’s executive chair, Dr. Hao Zeng, to explore the highlights of the meeting and the key areas for enhancing diagnostic and treatment capabilities for grassroots physicians in uro-oncolog

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West

By Mourabit Halima 2024.12.10

Upper tract urothelial carcinoma (UTUC), encompassing renal pelvic and ureteral cancers, is relatively rare, with unique characteristics in the Chinese population, such as distinct disease features and molecular biology profiles. The 8th West China Uro-Oncology Tianfu Academic Conference, recently held in Chengdu, provided a platform to discuss how to better address the challenges in UTUC treatment and improve patient outcomes. In this event, Oncology Frontier interviewed Dr. Yige Bao from West China Hospital of Sichuan University, who shared insights into personalized perioperative treatment of UTUC with ADC drugs and the hospital's clinical experiences.

CCHIO 2024丨Dr. Gang Zhu: Enhancing Patient Rehabilitation Concepts and Individualized Treatment for Multistage Benefits in Prostate Cancer Patients

By Mourabit Halima 2024.12.10

With economic development, lifestyle changes, and environmental factors, prostate cancer incidence in China has significantly increased. Screening high-risk populations and providing precision treatment and rehabilitation support based on patient characteristics are crucial for improving cure rates and quality of life. At the 2024 Chinese Congress of Holistic Integrative Oncology (CCHIO), Dr. Gang Zhu, Chair of the Urological Oncology Rehabilitation Committee of the Chinese Anti-Cancer Association and Director of General Surgery and Urology at United Family Healthcare, presented insights on individualized treatment for prostate cancer. Urology Frontier had the opportunity to delve deeper into this topic with Professor Zhu.

CCHIO 2024丨Dr. Xiufeng Liu: Exploring the Clinical Potential of the “Cola Combination” from LEAP-002 to LEAP-012

By Mourabit Halima 2024.12.06

The era of immunotherapy has brought new hope to advanced hepatocellular carcinoma (HCC), with various targeted-immune combination therapies emerging as potential breakthroughs. However, the journey of the "Cola Combination"—pembrolizumab combined with lenvatinib—has been marked by mixed results. In the LEAP-002 trial, the combination showed negative results in the general population but positive outcomes in the Asian subgroup. The LEAP-012 trial further demonstrated the combination's efficacy when paired with transarterial chemoembolization (TACE) in intermediate-stage HCC. Yet, its precise role in clinical practice remains under discussion.

Dr. Yige Bao: Perioperative Personalized Treatment of UTUC Based on ADC Drugs and the West China Experience

By Mourabit Halima 2024.12.02

The 8th West China Uro-Oncology Tianfu Academic Conference丨Dr. Hongzhen Li: Advances in Radiotherapy for Urothelial Carcinoma

By El Bachir MOURABIT 2024.12.02

Urothelial carcinoma (UC) is one of the most common malignant tumors of the urinary system, encompassing bladder cancer, renal pelvic cancer, and ureteral cancer. Radiotherapy, as a critical treatment modality for tumors, has gained prominence in the comprehensive treatment of UC, offering hope for improved survival outcomes. During the 8th West China Urologic Oncology Academic Conference held in Chengdu, Oncology Frontier invited Dr. Hongzhen Li from Peking University First Hospital to share the latest advancements in radiotherapy for UC.

2024 WAAW丨Dr. Pengfei Shen: Why Urinary Tract Infections Trouble Women？

By Mourabit Halima 2024.12.02

The third week of every November marks World Antimicrobial Awareness Week (WAAW). This year, WAAW adopts the theme: "Educate, Advocate, Act," aiming to raise public awareness about antimicrobial drugs, advocate for their appropriate use, and encourage action to combat antimicrobial resistance (AMR). In response to this call, Oncology Frontier invited Dr. Pengfei Shen from West China Hospital of Sichuan University to provide an informative overview of female urinary tract infections (UTIs), exploring why women are more prone to these infections, common symptoms, frequently used antibiotics, and the importance of responsible medication use to prevent antibiotic resistance.

Dr. Jun Guo: Reflecting on Progress in Renal Cancer Treatment and Pioneering a New Era of Cellular Therapy for Metastatic Patients

By Mourabit Halima 2024.11.25

Renal cancer is one of the three major malignancies in the urinary system, with advanced metastatic renal cancer having a poor prognosis and an overall five-year survival rate of less than 20%. Recent advances in targeted therapies and immunotherapies have led to significant improvements in treatment outcomes; however, for patients progressing beyond first-line therapies, the quest to extend survival remains an ongoing challenge. At the recently held 8th West China Uro-Oncology Tianfu Academic Conference, Dr. Jun Guo from Peking University Cancer Hospital shared insights into "Future Trends in Cellular Therapy for Renal Cancer," offering new hope for these patients. Following the conference, Oncology Frontier invited Professor Guo to provide further insights.

Dr. Kan Gong: Reflecting on Key Challenges and Hotspots in Renal Cancer Diagnosis and Treatment in China, Exploring New Frontiers in Translational Research | The 8th West China Uro-Oncology Tianfu Academic Conference

By Peng Longmei 2024.11.25

Renal cancer is one of the three major malignancies in the urinary system. Early-stage renal cancer often presents with concealed symptoms, making it difficult to differentiate between benign and malignant tumors. Advanced renal cancer primarily relies on targeted or immunotherapy, yet the effectiveness of existing targeted drugs is low, and resistance tends to develop easily. Therefore, conducting targeted translational research based on clinical problems offers hope for improving the current state of renal cancer diagnosis and treatment in China. At the 8th West China Uro-Oncology Tianfu Academic Conference held in Chengdu, Oncology Frontier invited Dr. Kan Gong from the Institute of Urology at Peking University and the Department of Urology at Peking University First Hospital to share insights into the current state of renal cancer diagnosis and treatment in China, as well as the highlights of his team’s work in translational research.